Zag Bio is a group of bold scientists and expert drug developers, formed to pioneer thymus-targeted medicines to treat and prevent autoimmune diseases. We have discovered a novel therapeutic approach to restore central immune tolerance by creating bifunctional antibodies that deliver self-antigens to specialized antigen-presenting cells in the thymus. This enables us to harness the body's natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body's own tissues. Zag Bio's pipeline includes its lead program ZAG-101, a bifunctional antibody that delivers pancreatic beta cell antigens to the thymus to treat Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases. Zag Bio is located in Cambridge, MA, and is supported by a broad syndicate of life sciences investors. Zag Bio's team is built on the mission of improving the lives of patients by charting a new direction for better therapies for autoimmune diseases, based on unique insights and understanding of the biology of the thymus.